Tiziana Life Sciences Ltd. ( TLSA ) is a biotech company that develops Foralumab, an anti-CD3 monoclonal antibody. This was designed for intranasal delivery to modulate immune responses in the brain. Foralumab aims to induce regulatory T cells (Tregs) and calmMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degre ...

Tiziana Life Sciences Ltd. ( TLSA ) is a biotech company that develops Foralumab, an anti-CD3 monoclonal antibody. This was designed for intranasal delivery to modulate immune responses in the brain. Foralumab aims to induce regulatory T cells (Tregs) and calmMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degre ...

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to adv ...

订阅服务 - Biotech Analysis Central提供制药公司的深度分析服务 每月订阅费49美元 年度订阅可享受3350%折扣 年费399美元 [1] - 服务内容包括600多篇生物科技投资文章 10多只中小盘股票的投资组合模型 实时聊天以及各类分析和新闻报告 [2] 公司研究 - 文章提及Tiziana Life Sciences (NASDAQ: TLSA)及其药物Foralumab的研发进展 [2]

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing bre ...